GlobeNewswire
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
📈
AI Sentiment
Highly Positive
8/10
AEON Biopharma Inc. News
Latest updates and market news for AEON
1 news
Mar 19 - Mar 25, 2026
Page 1
Share this news page